A 2023 study in JAMA revealed glucagon-like peptide-1 (GLP-1) receptor agonist drugs prescribed for diabetes and weight loss increase your risk for pancreatitis, gastroparesis and bowel obstruction
These drugs include the two most popular GLP-1 receptor agonists semaglutide (Ozempic) and liraglutide (Saxenda and Victoza). They are part of the rising demand for prescription weight loss medication that skyrocketed by 2,082% from 2019 to 2022
GLP-1 receptor agonists mimic the body’s natural hormone, trigger the slowing of the gastrointestinal tract and delay stomach emptying so the user feels full longer
Data show that while participants in the studies did lose weight, once the $1,000 per month medication was withdrawn, most participants regained two-thirds of the weight lost
Using weight loss drugs could lead to permanent, debilitating health problems and it’s likely you will regain the weight when you stop. Better solutions address the fundamental reason people gain weight — insulin resistance secondary to mitochondrial dysfunction from excess reductive stress

Posted in

Iron Will

Leave a Comment

You must be logged in to post a comment.